JNJ-56021927 (ARN-509)

apalutamide · Aragon Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-56021927 (ARN-509), covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

See pricing